MarketPulse

protein degradation

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arvinas Wins Historic PROTAC Approval; Eyes Q1 2026 Results on May 12

Arvinas wins landmark FDA approval for VEPPANU, first PROTAC protein degrader for breast cancer, ahead of schedule. Reports Q1 2026 results May 12.
PFEARVNFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Neomorph Raises $100M Series B to Accelerate Molecular Glue Degrader Pipeline

Neomorph closes $100M Series B led by Deerfield Management to advance NEO-811, its molecular glue degrader for kidney cancer, and expand its pipeline.
REGNclinical trialbiotechnology
GlobeNewswire Inc.GlobeNewswire Inc.··Amphista Therapeutics

Amphista Therapeutics Showcases Next-Gen Cancer Degraders at AACR Meeting

Amphista Therapeutics presents three programs at AACR 2026, including oral presentation on AMX-883 BRD9 degrader for AML treatment.
LLYNVScancer treatmentprotein degradation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arvinas to Showcase ARV-102 Parkinson's Data at Major Neurology Conference

Arvinas will present Phase 1 data for ARV-102, a PROTAC LRRK2 degrader, at AD/PD 2026 conference in Copenhagen, with Phase 1b trial planned for progressive supranuclear palsy.
ARVNPhase 1 clinical trialParkinson's disease